• Home
  1. Home
  2. Riociguat for pulmonary arterial hypertension associated with congenital heart disease
Scientific article
OA Policy
English

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

Contributors

Rosenkranz, Stephan; Ghofrani, Hossein-Ardeschir; Beghetti, Maurice; Ivy, Dunbar; Frey, Reiner; Fritsch, Arno; Weimann, Gerrit; Saleh, Soundos; Apitz, Christian

Published in

Heart, vol. 101, no. 22, p. 1792-1799

Publication date

2015

Abstract

The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explore the efficacy and safety of riociguat in the subgroup of patients with persistent/recurrent PAH after correction of congenital heart disease (PAH-CHD) from the PATENT studies.

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

ROSENKRANZ, Stephan et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. In: Heart, 2015, vol. 101, n° 22, p. 1792–1799. doi: 10.1136/heartjnl-2015-307832

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1468-201X
557views
531downloads

Technical informations

Creation

17/09/2015 12:52:00

First validation

17/09/2015 12:52:00

Update

14/03/2023 23:44:32

Status update

14/03/2023 23:44:32

Last indexation

31/10/2024 01:38:40
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated